Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy

BACKGROUND: Granulocyte colony-stimulating factors such as filgrastim are used to decrease the incidence of febrile neutropenia (FN) among patients with nonmyeloid cancers undergoing chemotherapy treatment. Although the biosimilar filgrastim-sndz has been approved in the United States since 2015, li...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartzberg, Lee S., Lal, Lincy S., Balu, Sanjeev, Campbell, Kim, Brekke, Lee, DeLeon, Andrew, Elliott, Caitlin, Korrer, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397873/
https://www.ncbi.nlm.nih.gov/pubmed/29687743
http://dx.doi.org/10.18553/jmcp.2018.17447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397873/
https://www.ncbi.nlm.nih.gov/pubmed/29687743
http://dx.doi.org/10.18553/jmcp.2018.17447

Ejemplares similares